Exact Therapeutics AS
OSE:EXTX
Operating Margin
Exact Therapeutics AS
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
NO |
E
|
Exact Therapeutics AS
OSE:EXTX
|
184.7m NOK | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
365.1B USD |
31%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
159.5B USD |
31%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
147B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.7B USD |
39%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
130.9B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.8B USD |
29%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
58.8B USD |
-7%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Exact Therapeutics AS
Glance View
EXACT Therapeutics AS is a clinical stage biopharmaceutical company, which engages in the research and development of novel platform for ultrasound mediated therapeutic amplification. The company is headquartered in Oslo, Oslo and currently employs 8 full-time employees. The company went IPO on 2020-07-14. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The firm's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. The company is done through harnessing the power of ultrasound in combination with ACT formulation.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Exact Therapeutics AS's most recent financial statements, the company has Operating Margin of 0%.